Estrogen receptor 1 mutations (ESR1m) are acquired in approximately 30% to 40% of patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), advanced breast cancer (ABC) who have developed resistance to first-line aromatase inhibitor (AI) plus cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy [1]. Although treatment decisions were traditionally guided by radiological progression, circulating tumor DNA (ctDNA) monitoring can detect emergent ESR1m clones 3 to 6 months preprogression [2]. The phase III PADA-1 study demonstrated that switching to fulvestrant based on ctDNA-detected ESR1m (without radiological progression) substantially extended median progression-free survival (PFS) versus continued AI (11.9 months vs. 5.7 months; hazard ratio [HR] = 0.61, 95% confidence interval [CI] = 0.43 to 0.86, P = 0.004) [3]. Similarly, the SERENA-2 trial demonstrated superior PFS with the novel oral selective estrogen receptor degrader (SERD) camizestrant compared to fulvestrant in ESR1-mutated ABC [4].